Clinical Assessment of a HYDRAGLYDE® Regimen
- Conditions
- HypermetropiaRefractive ErrorsMyopia
- Registration Number
- NCT03026257
- Lead Sponsor
- Alcon, a Novartis Company
- Brief Summary
The purpose of this study is to evaluate worn AIR OPTIX® plus HYDRAGLYDE® (AOHG) lenses cleaned and disinfected with HYDRAGLYDE® containing lens solutions compared to each of the control habitual silicone hydrogel (SiHy) lenses cleaned and disinfected with habitual multi-purpose solution (MPS) for cholesterol uptake.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 323
- Must sign informed consent document;
- Vision correctable to 0.1 (LogMAR) or better in each eye at distance with habitual lenses;
- Manifest cylinder (at screening) less than or equal to 0.75 diopter (D) in each eye and spectacle add <+0.50 D in each eye;
- Current full-time wearer of spherical samfilcon A, comfilcon A, senofilcon C monthly or senofilcon A 2-week replacement lens within the power range of lens powers available;
- Current user of an MPS (excluding OFPM) to care for lenses;
- Willing to answer text messages on a daily basis during the study;
- Willing to discontinue artificial tears during the study and rewetting drops on the days of study visits;
- Use of digital devices (eg, smart phone, tablet, laptop or desktop computer) for 20 consecutive minutes at least twice a week and willing to continue for the duration of the study;
- Other protocol specific inclusion criteria may apply.
- Habitual lens wear in an extended wear modality (routinely sleeping in lenses overnight for 1 or more nights per week);
- Any anterior segment infection, inflammation, disease or abnormality that contraindicates contact lens wear;
- History of herpetic keratitis, corneal surgery or irregular cornea;
- Prior refractive surgery;
- Any use of systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator;
- Currently using or have not discontinued Restasis®, Xiidra™ and/or topical steroids within the past 7 days;
- Use of mechanical eyelid therapy or eyelid scrubs within 14 days before Visit 1 and not willing to discontinue during the study;
- Monocular (only 1 eye with functional vision) or fit with only 1 lens;
- Known pregnancy or lactating;
- Other protocol specific exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Ex Vivo Total Cholesterol Uptake at Day 30 Day 30 The contact lens worn in the right eye was removed and stored dry and frozen until analysis. Total cholesterol uptake (cholesterol and cholesterol esters) was evaluated from a sample of the right contact lenses from each site and measured in micrograms. Lower total cholesterol uptake indicates increased lens performance.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Alcon Investigative Site
🇩🇪Jena, Germany
Alcon Investigative Site🇩🇪Jena, Germany